Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation

Anand P. Jillella, Martha L. Arellano, Leonard T. Heffner, Manila Gaddh, Amelia A. Langston, Hanna J. Khoury, Abhishek Mangoankar, Vamsi K. Kota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.

Original languageEnglish (US)
Article number7083
Pages (from-to)102-105
Number of pages4
JournalHematology Reports
Volume9
Issue number3
DOIs
StatePublished - Sep 26 2017

Fingerprint

Jehovah's Witnesses
Acute Promyelocytic Leukemia
Mortality
Disseminated Intravascular Coagulation
Leukemia
Population

Keywords

  • Acute Promyelocytic leukemia
  • Early deaths
  • Jehovah Witness

ASJC Scopus subject areas

  • Hematology

Cite this

Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation. / Jillella, Anand P.; Arellano, Martha L.; Heffner, Leonard T.; Gaddh, Manila; Langston, Amelia A.; Khoury, Hanna J.; Mangoankar, Abhishek; Kota, Vamsi K.

In: Hematology Reports, Vol. 9, No. 3, 7083, 26.09.2017, p. 102-105.

Research output: Contribution to journalArticle

Jillella, AP, Arellano, ML, Heffner, LT, Gaddh, M, Langston, AA, Khoury, HJ, Mangoankar, A & Kota, VK 2017, 'Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation', Hematology Reports, vol. 9, no. 3, 7083, pp. 102-105. https://doi.org/10.4081/hr.2017.7083
Jillella, Anand P. ; Arellano, Martha L. ; Heffner, Leonard T. ; Gaddh, Manila ; Langston, Amelia A. ; Khoury, Hanna J. ; Mangoankar, Abhishek ; Kota, Vamsi K. / Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation. In: Hematology Reports. 2017 ; Vol. 9, No. 3. pp. 102-105.
@article{451c9ce0d7464fc482b57acb7b42772b,
title = "Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation",
abstract = "Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.",
keywords = "Acute Promyelocytic leukemia, Early deaths, Jehovah Witness",
author = "Jillella, {Anand P.} and Arellano, {Martha L.} and Heffner, {Leonard T.} and Manila Gaddh and Langston, {Amelia A.} and Khoury, {Hanna J.} and Abhishek Mangoankar and Kota, {Vamsi K.}",
year = "2017",
month = "9",
day = "26",
doi = "10.4081/hr.2017.7083",
language = "English (US)",
volume = "9",
pages = "102--105",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s witness congregation

AU - Jillella, Anand P.

AU - Arellano, Martha L.

AU - Heffner, Leonard T.

AU - Gaddh, Manila

AU - Langston, Amelia A.

AU - Khoury, Hanna J.

AU - Mangoankar, Abhishek

AU - Kota, Vamsi K.

PY - 2017/9/26

Y1 - 2017/9/26

N2 - Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.

AB - Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.

KW - Acute Promyelocytic leukemia

KW - Early deaths

KW - Jehovah Witness

UR - http://www.scopus.com/inward/record.url?scp=85033238170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033238170&partnerID=8YFLogxK

U2 - 10.4081/hr.2017.7083

DO - 10.4081/hr.2017.7083

M3 - Article

AN - SCOPUS:85033238170

VL - 9

SP - 102

EP - 105

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 3

M1 - 7083

ER -